№2_2022

ONCOLOGY
BULLETIN
OF THE VOLGA REGION Vol. 13, no. 2. 2022
кардиоваскулярной токсичности противоопухолевой
лекарственной терапии //
Злокачественные опухоли: Практические
рекомендации RUSSCO #3s2. — 2019. — T. 9. —
C. 609-627.
11. Swain S.M., Whaley F.S., Ewer M.S. Congestive
heart failure in patients treated with doxorubicin:
a retrospective analysis of three trials // Cancer.
— 2003. — Vol. 97, №11. — P. 2869-79.
12. Legha S.S., Benjamin R.S., Mackay B., et al.
Reduction of doxorubicin cardiotoxicity by
prolonged continuous intravenous infusion //
Ann Intern. Med. — 1982. — 96. — P. 133-9.
13. Perez E.A., Suman V.J., Davidson N.E., et al.
Effect of doxorubicin plus cyclophosphamide
on left ventricular ejection fraction in patients
with breast cancer in the North Central Cancer
Treatment Group N9831 Intergroup Adjuvant
Trial // J. Clin. Oncol. — 2004. — 22. — P. 3700-4.
14. Mercuro G., Cadeddu C., Piras A., et al.
Early epirubicin-induced myocardial
dysfunction revealed by serial tissue
doppler echocardiography: correlation with
inflammatory and oxidative stress markers //
Oncologist. — 2007. — 12. — P. 1124-33.
doi:10.1634/theoncologist.12-9-1124.
15. Wadugu B., Kühn B. The role of neuregulin/
ErbB2/ErbB4 signaling in the heart with special
focus on effects on cardiomyocyte proliferation //
Am. J. Physiol Heart Circ Physiol. — 2012. — 302.
— H2139-H2147.
doi:10.1152/ajpheart.00063.2012
16. Tajik R., Saadat H., Taherkhani M. Angina induced
by 5-fluorouracil infusion in a patient with normal
coronaries // Am. Heart Hosp. J. — 2010. — 8. —
2E111-2. doi:10.15420/ ahhj.2010.8.2.111.
17. Jones R.L., Ewer M.S. Cardiac and cardiovascular
toxicity of nonanthracycline anticancer drugs
// Expert Rev. Anticancer Ther. — 2006. — 6. —
P. 1249-69. doi:10.1586/14737140.6.9.1249
18. Аншелес А.А., Сергиенко И.В., Сергиенко В.Б.
Современное состояние и перспективные
технологии радионуклидной диагностики в
кардиологии // Кардиология. — 2018. — T. 58,
№6. — C. 61-69.
19. Larsen C.M., Mulvagh S.L. Cardio-oncology: what
you need to know now for clinical practice and
echocardiography // Echo Res. Prat. — 2017. —
4. — 1. — P. 33-41. doi:10.1530/ERP-17-0013.
20. Lyon A., Dent S., Stanway S., et al. Baseline
cardiovascular risk assessment in cancer patients
scheduled to receive cardiotoxic cancer therapies:
a position statement and new risk assessment
tools from the Cardio-Oncology Study Group of
the Heart Failure Association of the European
Society of Cardiology in collaboration with the
International Cardio-Oncology Society // Eur.
J. Heart Fail. — 2020. — 22 (11). — P. 1945-60.
doi:10.1002/ejhf.1920.
21. Fei H.W., Ali M.T., Tan T.C., et al. Left Ventricular
Global Longitudinal Strain in HER-2 + Breast
Cancer Patients Treated with Anthracyclines
and Trastuzumab Who Develop Cardiotoxicity
Is Associated with Subsequent Recovery of Left
Ventricular Ejection Fraction // Echocardiography.
— 2016. — 33 (4). — P. 519-26. doi:10.1111/
echo.13168.
22. Васюк Ю.А., Ющук Е.Н., Несветов В.В. Кардиоонкология:
новый вызов нашего времени.
Сердечно-сосудистые осложнения противоопухолевого
лечения. — М.: Клинмедконсалтинг,
2019. — С. 100.
23. Thavendiranathan P., Poulin F., Lim K.D.,
et al. Use of myocardial strain imaging by
echocardiography for the early detection of
cardiotoxicity in patients during and after cancer
chemotherapy: a systematic review // J. Am. Coll
Cardiol. — 2014. — Vol. 63, №25 Pt A. — P. 2751-68.
24. Mousavi N., Tan T.C., Ali M., et al. Echocardiographic
parameters of left ventricular size and function
as predictors of symptomatic heart failure in
patients with a left ventricular ejection fraction
of 50-59% treated with anthracyclines // Eur.
Heart J. Cardiovasc. Imaging. — 2015. — 16 (9).
— P. 977-84. doi:10.1093/ehjci/jev113
25. Tian M., Nishijima Y., Asp M.L., et al. Cardiac
alterations in cancer-induced cachexia in mice
// Int. J. Oncol. — 2010. — 37. — P. 347-53.
doi:10.3892/ijo_00000683.
26. Negishi K., Negishi T., Haluska B.A., et al. Use
of speckle strain to assess left ventricular
responses to cardiotoxic chemotherapy and
cardioprotection // Eur. Heart J. Cardiovasc
Imaging. — 2014. — 15 (3). — P. 324-31.
doi:10.1093/ehjci/jet159
27. Pepe A., Pizzino F., Gargiulo P., et al.
Cardiovascular imaging in the diagnosis and
monitoring of cardiotoxicity: cardiovascular
Literature rewiew 109